secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nutex Health Inc. (NUTX)
CIK:        0001479681
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001628280-25-052898
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nutex Health restates 2024 results: revenue $479.9M (+93.8% YoY), net income $52.1M vs loss $45.8M
--------------------------------------------------------------------------------

- Restated full-year 2024: revenue $479.9M (up 93.8% YoY); net income $52.1M vs net loss $45.8M in 2023.
- Diluted EPS $9.69 vs diluted loss per share $10.39 in 2023; adjusted EBITDA $124.1M (up 1,046% YoY).
- Restatement adjustments: non-cash reclassifications increased liabilities $13.4M, decreased equity similarly; net income lowered ~$0.5M.
- Q4 2024 revenue $257.6M (+269.8% YoY); net income $61.6M vs net loss $31.6M in Q4 2023.
- Company notes stock repurchase program and arbitration process as ongoing; cash balance $40.6M at Dec 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479681/000162828025052898/0001628280-25-052898-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479681/000162828025052898/nutx-20251118.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-052898

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer